Pfizer Says Its Vaccine Is Safe in Kids 5-11 — Here’s What Comes Next

A smaller dose of Pfizer’s COVID-19 vaccine saw a “robust” immune response in children ages five to 11, according to data from Pfizer and BioNTech’s latest trial announced early Monday.

The companies said in a press release that the trials tested two-doses of 10 micrograms (a third of the adult/teen dosage of the Comirnaty vaccine ) with three weeks between doses and found that the vaccines produced a “robust” immune response within a month after their second dose and saw minimal side effects similar to those experienced by individuals age 16-25.

More from SheKnows

As SheKnows has previously reported , the Pfizer/Biotech vaccine is an mRNA vaccine (like the one from Moderna — both entirely different from the Johnson & Johnson vaccine ) have so far been cleared for and recommended for adults (including elderly, pregnant and breastfeeding adults) and children as young as 12. According to the CDC, mRNA vaccines “teach our cells how to make a protein—or even just a piece of a protein—that triggers an immune response inside our bodies. That immune response, which produces antibodies, is what protects us from getting infected if the real virus enters our bodies” instead of other vaccines that put weakened or inactive germs into our bodies to trigger an immune response.

“Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our COVID-19 vaccine. We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children,” Albert Bourla, Chairman and Chief Executive Officer, Pfizer, said in a press release. “Since July, pediatric cases of COVID-19 have risen by about 240 percent in the U.S. — underscoring the public health need for vaccination. These trial results provide a strong foundation for seeking authorization of our vaccine for children five to 11 years old, and we plan to submit them to the FDA and other regulators with urgency.”

Leave a Reply

Your email address will not be published. Required fields are marked *